Table 1.

Patient demographics, treatments prior to vedolizumab, treatments following vedolizumab induction, and clinical, endoscopic, and histologic improvement

Patient number	1	2	3	4	5
Current age (years)	39.7	22.7	28.2	35.3	53.7
Sex	Male	Male	Female	Male	Female
Race	White	White	White	White	White
Location of GI involvement1	S, SB, C	E, S, SB	E, S, SB	E, S, SB	S, SB
Duration of disease at vedo start (years)	8.1	17.2	11.3	13.1	6.5
Vedolizumab continued at end of follow-up	No	No	No	Yes	Yes
Last known treatment	Ustekinumab	Study drug	Study drug	--	--
Treatments
Prior to vedolizumab start
Swallowed fluticasone		Yes		Yes
Swallowed budesonide		Yes		Yes
Entocort	Yes	Yes	Yes		Yes
Systemic steroids	Yes	Yes	Yes	Yes	Yes
Omalizumab			Yes
Food elimination diet	Yes	Yes	Yes	Yes
Cromolyn	Yes	Yes	Yes	Yes
6MP/azathioprine2	Yes		Yes	Yes	Yes
Methotrexate	Yes	Yes	Yes
Infliximab	Yes
After vedolizumab start
Swallowed fluticasone		Yes
Swallowed budesonide
Entocort	Yes	Yes			Yes
Systemic steroids	Yes			Yes	Yes
Omalizumab
Food elimination diet		Yes	Yes
Cromolyn
6MP/azathioprine					Yes
Methotrexate
Infliximab
Stopped systemic steroids post induction	No	N/a	N/a	Yes	Yes
Length of vedolizumab course (years)	0.3	0.2	0.6	1.0	1.3
Number of infusions	4	3	5	10	16
Overall clinical improvement3	Yes	No	No	+/−	Yes
Endoscopic improvement	N/A4	No	No	No	No
Eosinophil counts (per hpf)
Esophagus
Diagnosis5	0	90	42	45	0
Baseline6	0	100	3	0	N/A
Post-vedolizumab7	N/A	100	24	3	N/A
Stomach
Diagnosis	210	80	23	400	230
Baseline	180	0	0	1	25
Post-vedolizumab	N/A	0	30	0	0
Duodenum
Diagnosis	0	N/A	80	0	170
Baseline	0	N/A	76	8	150
Post-vedolizumab	N/A	N/A	0	0	0
Jejunum
Diagnosis	N/A	40	N/A	40	140
Baseline	130	82	N/A	6	N/A
Post-vedolizumab	N/A	58	N/A	0	N/A

¹E: esophageal involvement, S: stomach involvement, SB: small bowel involvement, C: colonic involvement;

²6MP: 6-mercaptopurine;

³Patient 1 stopped due to adverse events of migraine and recurrent nasopharyngeal infections, and Patients 2 & 3 stopped due to lack of clinical, endoscopic, or histologic resposne;

⁴N/A: not assessed;

⁵Eosinophil counts at diagnosis or off treatments;

⁶Eosinophil counts at baseline prior to vedolizumab treatment, including patients on the treatments listed above;

⁷Eosinophil counts after vedolizumab treatment